Literature DB >> 11099496

Insufficient phosphorylation prevents fc gamma RIIB from recruiting the SH2 domain-containing protein-tyrosine phosphatase SHP-1.

R Lesourne1, P Bruhns, W H Fridman, M Daëron.   

Abstract

Fc gamma RIIB are IgG receptors that inhibit immunoreceptor tyrosine-based activation motif (ITAM)-dependent cell activation. Inhibition depends on an immunoreceptor tyrosine-based inhibition motif (ITIM) that is phosphorylated upon Fc gamma RIIB coaggregation with ITAM-bearing receptors and recruits SH2 domain-containing phosphatases. Agarose bead-coated phosphorylated ITIM peptides (pITIMs) bind in vitro the single-SH2 inositol 5-phosphatases (SHIP1 and SHIP2) and the two-SH2 protein tyrosine phosphatases (SHP-1 and SHP-2). Phosphorylated Fc gamma RIIB, however, recruit selectively SHIP1/2 in vivo. We aimed here at explaining this discordance. We found that beads coated with low amounts of pITIM bound in vitro SHIP1, but not SHP-1, i.e. behaved as phosphorylated Fc gamma RIIB in vivo. The reason is that SHP-1 requires its two SH2 domains to bind on adjacent pITIMs. Consequently, the binding of SHP-1, but not of SHIP1, increased with pITIM density on beads. When trying to increase Fc gamma RIIB phosphorylation in B cells and mast cells, we found that concentrations of ligands optimal for Fc gamma RIIB phosphorylation failed to induce SHP-1 recruitment. SHP-1 was, however, recruited by Fc gamma RIIB when hyperphosphorylated following cell treatment with pervanadate. Our data suggest that Fc gamma RIIB phosphorylation may not be sufficient in vivo to enable the recruitment of SHP-1 but that (pathological?) conditions that would hyperphosphorylate Fc gamma RIIB might enable SHP-1 recruitment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11099496     DOI: 10.1074/jbc.M006537200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Fc receptors as adaptive immunoreceptors.

Authors:  Marc Daëron
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

2.  Osteoclast inhibitory peptide-1 binding to the Fc gammaRIIB inhibits osteoclast differentiation.

Authors:  Srinivasan Shanmugarajan; Craig C Beeson; Sakamuri V Reddy
Journal:  Endocrinology       Date:  2010-07-07       Impact factor: 4.736

Review 3.  Regulation of hematopoietic cell function by inhibitory immunoglobulin G receptors and their inositol lipid phosphatase effectors.

Authors:  Carol T Cady; Jeffrey S Rice; Vanessa L Ott; John C Cambier
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

Review 4.  Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling.

Authors:  Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2015-11       Impact factor: 12.988

5.  Restricted accumulation of phosphatidylinositol 3-kinase products in a plasmalemmal subdomain during Fc gamma receptor-mediated phagocytosis.

Authors:  J G Marshall; J W Booth; V Stambolic; T Mak; T Balla; A D Schreiber; T Meyer; S Grinstein
Journal:  J Cell Biol       Date:  2001-06-25       Impact factor: 10.539

6.  Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation.

Authors:  Sanae Ben Mkaddem; Amaya Murua; Héloise Flament; Dimitri Titeca-Beauport; Carine Bounaix; Luca Danelli; Pierre Launay; Marc Benhamou; Ulrich Blank; Eric Daugas; Nicolas Charles; Renato C Monteiro
Journal:  Nat Commun       Date:  2017-08-15       Impact factor: 14.919

7.  IgG-Independent Co-aggregation of FcεRI and FcγRIIB Results in LYN- and SHIP1-Dependent Tyrosine Phosphorylation of FcγRIIB in Murine Bone Marrow-Derived Mast Cells.

Authors:  Mathias Gast; Christian Preisinger; Falk Nimmerjahn; Michael Huber
Journal:  Front Immunol       Date:  2018-08-27       Impact factor: 7.561

Review 8.  The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease.

Authors:  Jessica C Anania; Alicia M Chenoweth; Bruce D Wines; P Mark Hogarth
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

9.  Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.

Authors:  Oliver Parting; Samantha Langer; Maja Kim Kuepper; Caroline Wessling; Shaoguang Li; Till Braunschweig; Nicolas Chatain; Tiago Maié; Ivan G Costa; Martina Crysandt; Michael Huber; Tim H Brümmendorf; Steffen Koschmieder; Mirle Schemionek
Journal:  Leukemia       Date:  2020-07-20       Impact factor: 11.528

10.  Overexpression of FcγRIIB regulates downstream protein phosphorylation and suppresses B cell activation to ameliorate systemic lupus erythematosus.

Authors:  Linlin Sheng; Xiuqin Cao; Shuhong Chi; Jing Wu; Huihui Xing; Huiyu Liu; Zhiwei Yang
Journal:  Int J Mol Med       Date:  2020-08-07       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.